>

Theodore Samuelsto - Perrigo Company Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>PRG</div>
PRGO -- USA Stock  

0.225 Dividend

  Director
Mr. Theodore R. Samuelsto was appointed as an Independent Director of the Company, effective January 4, 2017. Mr. Samuels has served as President of Capital Guardian Trust Company, a Capital Group company, since 2010 and an equity portfolio manager and investment analyst at Capital Group since 1981. Capital Group is one of the most prominent investors inthe United Statesand globally, delivering longterm results for investors using highconviction portfolios, rigorous research, and individual accountability
  Director Since 2017  MBA    
353 1 709 4000  http://www.perrigo.com
Samuels has evaluated numerous companies across all sectors and has served on many management and investment committees, with an eye toward shareholder value creation. He holds a B.A. from Harvard College and an MBA from Harvard Business School.

Management Efficiency

The company has return on total asset (ROA) of 2.19 % which means that it generated profit of $2.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.32 % meaning that it created $4.32 on every $100 dollars invested by stockholders.
The company currently holds 3.5 B in liabilities with Debt to Equity (D/E) ratio of 60.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 2.03 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Leo PuriDr Reddys Laboratories Ltd
2018
Huda ZoghbiRegeneron Pharmaceuticals
2016
William DoyleZoetis
2015
Shikha SharmaDr Reddys Laboratories Ltd
2019
James KangOrigin Agritech Limited
2010
William SteereZoetis
2013
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Christine PoonRegeneron Pharmaceuticals
2010
Bharat DoshiDr Reddys Laboratories Ltd
2016
Sridar IyengarDr Reddys Laboratories Ltd
2011
Louise ParentZoetis
2013
David AltshulerVertex Pharmaceuticals Incorpor
2015
Omkar GoswamiDr Reddys Laboratories Ltd
2000
Anupam PuriDr Reddys Laboratories Ltd
2002
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Sanjay KhoslaZoetis
2013
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Bruce CarterDr Reddys Laboratories Ltd
2008
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
George SingRegeneron Pharmaceuticals
1988

Company Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, PresidentView
Gary Cohen, Independent DirectorView
Arthur Shannon, IR Contact OfficerView
Ronald Winowiecki, Acting CFOView
Svend Andersen, Executive Vice President and President - Consumer Healthcare InternationalView
Judy Brown, CFO and Executive VPView
Laurie Brlas, Independent DirectorView
Donal OConnor, Independent DirectorView
James Michaud, Chief Human Resource Officer, Executive Vice PresidentView
Louis Yu, Executive Vice President - Global QualityView
John Wesolowski, Executive Vice President and Presidentident - RXView
Theodore Samuelsto, Independent DirectorView
Scott Jamison, Executive Vice President General Manager - NutritionalsView
Ellen Hoffing, Independent DirectorView
Marc Coucke, Executive Vice President General Manager - Omega Pharma BusinessView
Adriana Karaboutis, Independent DirectorView
Michael Jandernoa, Independent DirectorView
Paul Weninger, Executive Vice President - Global Quality OperationsView
Thomas Farrington, Senior Vice President CIOView
Herman Morris, Independent DirectorView
Jeffrey Needham, Executive Vice President General Manager - Consumer HealthcareView
Todd Kingma, Executive VP, General Counsel and SecretaryView
Rolf Classon, Independent DirectorView
Raymond Silcock, CFOView
Shlomo Yanai, Independent Director NomineeView
Jatin Shah, Senior Vice President Chief Scientific OfficerView
Michael Stewart, Senior Vice President - Global Human ResourcesView
Jeffrey Kindler, Independent DirectorView
Jacqualyn Fouse, Independent DirectorView
Grainne Quinn, Executive Vice President Chief Medical OfficerView
Theodore Samuels, Independent DirectorView
Geoffrey Parker, Independent DirectorView
Murray Kessler, President CEO, DirectorView
Sharon Kochan, Executive VP and General Manager of InternationalView
Gary Kunkle, Lead Independent DirectorView
Joseph Papa, Chairman and CEOView
Marry Brlas, Independent Chairman of the BoardView
Bradley Alford, Independent DirectorView
Jeffrey Smith, Independent DirectorView
Bradley Joseph, IR Contact OfficerView
James Dillard, Executive Vice President Chief Scientific OfficerView
Douglas Boothe, Executive Vice President General Manager - Rx PharmaceuticalsView
Ronald Janish, Executive Vice President - Global Operations and Supply ChainView
Uwe Rohrhoff, President CEO, DirectorView

Stock Performance Indicators

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module

Currently Active Assets on Macroaxis

GM   
Purchased over 100 shares of
a day ago
Traded for 30.71
ECA   
Purchased over 500 shares of
a day ago
Traded for 3.54
GM   
Purchased over 100 shares of
a day ago
Traded for 30.71
WD   
Purchased over 40 shares of
a day ago
Traded for 66.38
DD   
Purchased over 70 shares of
a day ago
Traded for 43.18
Please check Your Equity Center. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.